These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2148009)

  • 21. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
    Turpin G; Bruckert E
    Atherosclerosis; 1996 Jul; 124 Suppl():S83-7. PubMed ID: 8831920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transitory deficit in high-density lipoproteins and apolipoprotein A-I.
    Legras B; Clerc C; Ruelland A; Doualin G; Fertil V; Cloarec L
    Clin Chem; 1990 Mar; 36(3):580-1. PubMed ID: 2107044
    [No Abstract]   [Full Text] [Related]  

  • 23. [Acute rhabdomyolysis associated with digestive disorders during a voluntary overdose of ciprofibrate].
    Giraud O; Chanu B; Farge D; Parrot F; Brestescher C; Rouffy J
    Gastroenterol Clin Biol; 1995 Feb; 19(2):231-2. PubMed ID: 7750722
    [No Abstract]   [Full Text] [Related]  

  • 24. [Drug-induced myopathies].
    Ando H; Fujimura A
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():390-3. PubMed ID: 18074569
    [No Abstract]   [Full Text] [Related]  

  • 25. Creatinine rise after fibrate therapy in renal graft recipients.
    Devuyst O; Goffin E; Pirson Y; van Ypersele de Strihou C
    Lancet; 1993 Mar; 341(8848):840. PubMed ID: 8096050
    [No Abstract]   [Full Text] [Related]  

  • 26. Fibrate-induced increase in blood urea and creatinine.
    Lipscombe J; Bargman JM
    Nephrol Dial Transplant; 2001 Jul; 16(7):1515. PubMed ID: 11427661
    [No Abstract]   [Full Text] [Related]  

  • 27. CORONARY EFFECT OF FIBRATES ON PROTEINS AND ENZYMES WHICH HYDROLYZE TRIACYLGLYCEROLS.
    Francik R; Kryczyk J; Francik S
    Acta Pol Pharm; 2016; 73(3):579-88. PubMed ID: 27476274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacokinetics of antilipemic agents. 4. Biotransformation of the antilipemic agent ciprofibrate (2-(4-(2,2-dichlorcyclopropyl)-phenoxy)-2-methylpropionic acid)].
    Oelschläger H; Rothley D; Schmidt W
    Arch Pharm (Weinheim); 1988 Jun; 321(6):367-70. PubMed ID: 3178437
    [No Abstract]   [Full Text] [Related]  

  • 29. [The pharmacokinetics of antilipemic agents. 5. Is 2-(4-hydroxyphenoxy)-2-methylpropionic acid a metabolite of the antilipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Jun; 322(6):337-42. PubMed ID: 2774869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The pharmacokinetics of hypolipemic agents. 6. Is 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-propane a metabolite of the hypolipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Oct; 322(10):629-32. PubMed ID: 2624522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
    Maiguma T; Fujisaki K; Itoh Y; Makino K; Teshima D; Takahashi-Yanaga F; Sasaguri T; Oishi R
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):289-96. PubMed ID: 12644902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Conjugation reactions of ciprofibrate with human and laboratory animals].
    Oelschläger H; Müller D; Hellwich KH; Ueberall S; Seeling A; Machts H; Hofmann B; Glöckner R
    Arzneimittelforschung; 2003; 53(4):247-53. PubMed ID: 12785120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.
    Lupp A; Karge E; Deufel T; Oelschlägers H; Fleck C
    Arzneimittelforschung; 2008; 58(5):225-41. PubMed ID: 18589557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
    Ferry N; Bernard N; Pozet N; Gardes E; Cuisinaud G; Labeeuw M; Zech PY; Sassard J
    Br J Clin Pharmacol; 1989 Dec; 28(6):675-81. PubMed ID: 2611089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The enantiomeric resolution of ciprofibrate and related compounds by HPLC using chiral stationary phases.
    Anderson NH; Johnston D; Vojvodic PR
    J Pharm Biomed Anal; 1992 Jul; 10(7):501-5. PubMed ID: 1420475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
    Gajdos M; Fedelesova V; Mongiellova V; Cibulova L; Huttova D; Polak F; Krivosikova Z
    Bratisl Lek Listy; 1999 Aug; 100(8):449-53. PubMed ID: 10645034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The pharmacokinetics of hypolipemic agents. 10. The dehalogenation of the hypolipemic agent ciprofibrate].
    Oelschläger H; Hellwich KH; Rothley D
    Arch Pharm (Weinheim); 1994 Apr; 327(4):261-5. PubMed ID: 8204026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of ciprofibrate on gastric secretion in the rat.
    Eason CT; Pattison A; Howells DD; Bonner FW
    J Pharm Pharmacol; 1988 Jul; 40(7):512-3. PubMed ID: 2904995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative and simultaneous effects of simvastatin and ciprofibrate on plasma lipid parameters and upon hepatic drug metabolizing and peroxisome proliferation marker enzymes in the male Wistar rat.
    Charmoillaux M; Goudonnet H; Mercenne F; Mounié J; Truchot RC
    Cell Mol Biol; 1991; 37(8):765-71. PubMed ID: 1807786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Ciprofibrate: erythrocyte partition coefficient and binding to serum protein].
    Czejka M
    Arch Pharm (Weinheim); 1991 May; 324(5):287-9. PubMed ID: 1888266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.